UNITED STATES SECURITIES AND EXCHANGE COMMISSION  Washington, D.C.  20549  FORM
10-K/A   [X] ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the fiscal year ended November 30, 2008  [ ] TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from
__________________ to __________________  Commission File Number: 000-49817  GENOSYS, INC. (Exact Name of Registrant as specified in
its Charter)   Utah
87-0671592(State or other jurisdiction of
incorporation or organization)
(IRS Employer Identification
No.)  280 W. Riverpark Drive, Provo, UT
84604 (Address of Principal Executive Offices)  Registrants Telephone Number, including
area code:  (801) 623-4751  Securities Registered pursuant to Section
12(b) of the Act:  None  Securities Registered pursuant to Section
12(g) of the Act:  Common Stock, par value $0.001 per share (Title of Class)  Indicate by check mark if the Registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  [
  ]     No  [ X ]  Indicate by check mark if the Registrant is not required
to file reports pursuant to Section 13 or 15(d) of the Exchange Act.
   Yes  [   ]    No  [X]  Indicate by check mark whether the Registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the Exchange
Act during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes  [ X ]   No
  [   ]  Indicate by check mark if disclosure of delinquent filers
pursuant to item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of Registrants knowledge, in definitive proxy or
information statements incorporated by reference in Part IV of this Form 10-K or
any amendment to this Form 10-K. [   ]   1    Indicate by
check mark whether the Registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer or a smaller reporting company:  Large accelerated
filer       [   ]
Accelerated filed
                    [ 
 ]Non-accelerated
filer         [ 
 ]
Smaller reporting
company    [X]  Indicate by check mark whether the Registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). Yes   [   ]
    No  [ X ].  Aggregate Market Value of Non-Voting
Common Stock Held by Non-Affiliates  State the aggregate market value of the
voting and non-voting common stock held by non-affiliates computed by reference
to the price at which the common stock was last sold, or the average bid and
asked price of such common stock, as of the last business day of the
Registrants most recently completed second quarter.  The market value of the voting and
non-voting common stock presently held by non-affiliates is $2,847,024, based on
14,984,336 shares held by non-affiliates.  These shares were valued at the
last trade of the Registrants common stock on the OTCBB on March 12, 2009, of
$0.19 per share.  Applicable Only to Registrants Involved
in Bankruptcy Proceedings During the Preceding Five Years  Not applicable.  Outstanding Shares  As of March 12, 2009, the Registrant had
47,666,774 shares of common stock outstanding.  Documents Incorporated by
Reference  See Part IV, Item
15.  Explanatory
Note:  This Annual Report is
being amended to correct our 302 certifications only.     2     SIGNATURES  Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the
Registrant has duly caused this Annual Report to be signed on its behalf by the
undersigned, thereunto duly authorized.  GeNOsys,
Inc.  Date: 4/13/2009
                 By/s/John
W. R. Miller John
W. R. Miller, Jr., Director and
Chief Executive Officer  Date: 4/13/2009
                 By/s/Brett
A. Blake Brett
A. Blake President  Date: 4/13/2009
                 By/s/Keith
L. Merrell Keith
L. Merrell Chief
Financial Officer and Treasurer  Date: 4/13/2009
                 By/s/Clark
M. Mower Clark
M. Mower, Director and Chairman
of the Board  Date: 4/13/2009
                 By/s/John
P. Livingstone John
P. Livingstone Director  Date: 4/13/2009
                 By/s/Stephen
D. Minton, M.D. Stephen
D. Minton, M.D., Director and
Chief Medical Officer   3